Does chemotherapy or radiotherapy affect the postoperative complication in patients who underwent immediate breast reconstruction with tissue expander?

Sung Mi Jung
   Samsung medical center  https://orcid.org/0000-0003-2820-8797

Byung-Joon Jeon
   Samsung Medical Center

Jinsun Woo
   Samsung Medical Center

Jai Min Ryu
   Samsung Medical Center

Se Kyung Lee
   Samsung Medical Center

Byung-Joo Chae
   Samsung Medical Center

Jonghan Yu
   Samsung Medical Center

Seok Won Kim
   Samsung Medical Center

Seok Jin Nam
   Samsung Medical Center

Sa Ik Bang
   Samsung Medical Center

Goo-Hyun Mun
   Samsung Medical Center

Jai-Kyong Pyon
   Samsung Medical Center

Jeong Eon Lee (jeongeon.lee@samsung.com)
   Samsung Medical Center  https://orcid.org/0000-0003-0037-2456

Research article
Abstract

Background: Immediate breast reconstruction with tissue expander in patients who were expected to receive adjuvant therapy, such as chemotherapy or radiotherapy, has been a topic of debate. Postoperative complications from tissue expander procedures can delay the timing of adjuvant treatment and subsequently increase the probability of recurrence. The purpose of this study was to identify the impact of chemotherapy and radiotherapy on postoperative complications in patients who underwent immediate reconstruction (IR) using tissue expander. Methods: We conducted a retrospective study of 1,081 breast cancer patients who underwent mastectomy and IR using tissue expander insertion between 2012 and 2017 in Samsung Medical Center. The patients were divided into two groups based on complications (complication group vs. no complication group). Complication group was regarded to have surgical removal or conservative treatment based on clinical findings such as infection, capsular contracture, seroma, hematoma, rupture, malposition, tissue viability, or cosmetic problem. The complication group had 59 patients (5.5%) and the no complication group had 1,022 patients (94.5%).

Results: In univariate analysis, adjuvant radiotherapy and adjuvant chemotherapy were significantly associated with postoperative complications. In multivariate analysis, however, only higher pathologic N stage was significantly associated with postoperative complications (p < 0.001). Chemotherapy (p = 0.775) or radiotherapy (p = 0.825) were not risk factors for postoperative complications. Conclusions: IR with tissue expander after mastectomy may be a treatment option even when the patients are expected to receive adjuvant chemotherapy or radiotherapy. These results will aid patients who are concerned about the complications of IR caused by chemotherapy or radiotherapy determine whether or not to have IR. Trial registration: Patients were selected and registered retrospectively, and medical records were evaluated.

Background

Breast cancer is the second most common cancer among women in the United States. In the United States, 250,520 new cases of female breast cancer were reported, and 42,000 women died of this cancer in 2017. For every 100,000 women, 125 new female breast cancer cases were reported and 20 women died of this cancer. The global burden of breast cancer in women, measured by incidence or mortality, is substantial and rising in several countries [1, 2].

Mastectomy with immediate reconstruction (IR) is one of the treatment option for breast cancer. Breast reconstruction after mastectomy has a positive impact on patients’ psychosocial and sexual well-being. Moreover, immediate breast reconstruction can provide patients with the opportunity to reduce one additional surgery and costs instead of undergoing two separate procedures [3-8].

The performance of mastectomy followed by IR with a tissue expander in patients who were expected to receive adjuvant chemotherapy or radiotherapy has been debated. It is important to identify how adjuvant chemotherapy or radiotherapy affects surgical site complications in patients who have undergone IR. Postoperative complications related to tissue expander can miss the timing of adjuvant chemotherapy or radiotherapy.
radiotherapy and subsequently increase the probability of recurrence. Some previous studies reported that the incidence of postoperative complications caused by chemotherapy or radiotherapy in patients with tissue expander was higher than in patients without tissue expander [9, 10]. Other studies have reported that immediate breast reconstruction may be a feasible surgical option in patients who were expected to receive adjuvant chemotherapy or radiotherapy and that it did not significantly affect the timing of adjuvant treatment or postoperative complications [11, 12].

The aim of this study was to determine the impact of chemotherapy and radiotherapy on postoperative complications in patients who received mastectomy and IR using tissue expander insertion.

Methods

Patients

This study was retrospectively performed on breast cancer patients who underwent mastectomy and IR using tissue expander from January 2012 to December 2017 in Samsung Medical Center. The inclusion criteria included a total of 1,081 female breast cancer patients who underwent nipple-sparing mastectomy or skin-sparing mastectomy with IR using tissue expander. The patients who received autologous reconstruction with deep inferior epigastric perforator free flap, latissimus dorsi flap or other tissues were excluded from this study (Fig. 1). There was no risk-reducing mastectomy case in the inclusion criteria. The pathologic breast cancer staging followed the National Comprehensive Cancer Network (NCCN) guidelines version 5.2020 and adjuvant therapy, such as chemotherapy or radiotherapy, was determined by stage and subtype [13].

Inclusion criteria were periodically monitored through physical examination, imaging and laboratory tests that were conducted at intervals of 6 months and 1 year, depending on the stage. The median follow-up was 448 days (range 27-2,423 days). The patients were divided based on postoperative complications (complication group vs. no complication group). Complication group was regarded not only to have surgical removal of the tissue expander or implant which inserted after removing the tissue expander, but also to receive conservative treatment without surgical removal. Clinicians decided whether to have surgical removal or conservative treatment based on clinical findings such as infection, capsular contracture, seroma, hematoma, rupture, malposition, tissue viability, or cosmetic problem according to the Clavien-Dindo classification (CDC); CDC show acceptance and reproducibility through presumed parameters of severity of morbidity by correlating the various grades of complications that do not require treatment, or require treatment such as medication or surgery, or lead to death [14]. Surgical site infection (SSI) was diagnosed if there were clinical symptoms such as erythema, discharge, abscess, febrile sense, swelling, or tenderness, with or without isolation of pathogenic bacteria by the judgement of the clinicians. Patients who had signs of infection received surgical removal or conservative treatment with antibiotics. Surgical intervention for SSI was performed if the signs of infection continued despite to empirical antibiotic treatment, or rapid treatment of SSI was required due to planned adjuvant chemotherapy or radiotherapy. Capsular contracture was regarded according to Baker classification
system with grade III (moderately contracture with firmness) or grade IV (severe contracture with symptom). Seroma or hematoma was considered as complication if surgical intervention or aspiration was required. Rupture or recurrence was found in breast ultrasound or magnetic resonance imaging performed during follow-up with clinical findings.

The data, including demographic factors, pathologic findings, and perioperative treatment were collected from the electronic medical records after Institutional Review Board Approval in Samsung Medical Center (IRB file no. 2019-10-146). Signed informed consent from the patients was not required.

Statistical analysis

Statistical analyses were performed using SPSS Statistics versions 25 (IBM Corp., Armonk, NY, USA). The continuous variables were compared using the Student's t test between the two groups and the results are described as the mean and standard deviation with the range. The Chi-squared test and Fisher's exact test were conducted to compare the categorical variables between the two groups and the categorical variables are reported as number and percentage. All significant risk factors for postoperative complications were analyzed in univariate and binary logistic regression for multivariate analysis. Confidence intervals (95%) and odds ratios were calculated and statistical significance was defined as $p < 0.05$ in all tests.

Results

Characteristics of patients

A total of 11,360 patients underwent surgery for breast cancer from January 2012 to December 2017 in Samsung Medical Center. Of these, 1,185 patients who underwent mastectomy with IR and 1,081 patients who underwent IR with tissue expander insertion were included. There were 1,022 patients (94.5%) without postoperative complications (no complication group) and 59 patients (5.5%) with postoperative complications (complication group) (Fig. 1). The median follow-up was 448 days (range 27-2,423 days).

The baseline characteristics of the patients between the two groups were well balanced. The mean age of the patients at the time of breast cancer surgery was 43.29 years in the no complication group and 42.29 years in the complication group. There was no significant difference in the number the patients less than 40 years old and those more than 40 years old between the two groups. The mean body mass index (BMI) was 21.96 kg/m$^2$ in the no complication group and 22.40 kg/m$^2$ in the complication group. There was no significant difference in the number of underweight, normal, or overweight patients defined by World Health Organization (WHO) criteria (Asia-Pacific region) between the two groups. The incidence of patients with a history of diabetes mellitus (DM) or smoking was not significantly different between the two groups. Prior smokers were defined as those who quit smoking more than six months earlier (Table 1).
The pathologic characteristics of lymphovascular invasion (LVI), pathologic N stage, and pathologic prognostic stage were significantly associated with postoperative complications. LVI was detected more often in the complication group than in the no complication group ($p = 0.001$). The proportion of patients with higher than pathologic T1 stage cancer was 91.5% in the complication group and 79.7% in the no complication group. The proportion of patients with higher than pathologic N1 stage cancer was 54.2% in the complication group and 24.9% in the no complication group. There was a significant difference in the proportion of patients who were diagnosed with pathologic prognostic stage III cancer ($p = 0.017$). Invasive cancer was diagnosed 77.8% patients, and there was no significantly difference in two groups. The patients with ER-positive or PR-positive were 77.9%, and with HER2-negative were 61.4% in two groups. The histologic feature and subtype were not significantly different between the two groups (Table 2).

There were significant differences in type of axillary surgery and adjuvant treatments. Patients in the complication group significantly more received axillary lymph node dissection and adjuvant post-mastectomy radiotherapy (PMRT) than patients in no complication group ($p < 0.001$) (Table 3).

**Risk factors of postoperative complications**

Postoperative complications developed in 59 patients. Twenty-three (39.0%) of the 59 patients developed infections, and empirical antibiotics are administered. Seventeen of the 23 patients were treated with surgical removal, and 14 of the 17 patients had SSI which isolated pathogenic bacteria. Six of the 23 patients were treated with antibiotics without the removal of tissue expanders, and 3 of the 6 patients had SSI which isolated pathogenic bacteria. One of 59 patients was diagnosed with brain metastasis and underwent removal of the tissue expander for brain magnetic resonance imaging scans. One of two patients with persistent seroma formation after adjuvant radiotherapy required the removal of the tissue expander. For cosmetic effects, one patient with rippling had re-operation to change her implant and one patient had scar revision (Table 4).

Eleven (18.6%) out of 59 patients recovered after conservative treatment without removal of the tissue expander or implant, and 48 (81.4%) other patients required operation for complications (Table 4). Fifteen (31.3%) out of 48 patients had their tissue expanders removed and 33 (68.8%) other patients had their implants removed, which were inserted after tissue expander removal. The median time from surgery to the initiation of the adjuvant treatment, chemotherapy or radiotherapy, was 30 days, and adjuvant treatment was delayed in six of 35 patients who required adjuvant chemotherapy or radiotherapy because postoperative complications developed. Five of six patients needed removal of their tissue expanders and one of six patients recovered after conservative treatment without removal of their tissue expander. Five of six patients delayed their adjuvant chemotherapy and one of six patients delayed adjuvant radiotherapy. The median time from mastectomy to complications was 620 days (range 27-2,423 days).

In univariate analysis, the pathologic results showed that LVI was associated with a higher risk of postoperative complication than that in patients without LVI ($HR = 2.499$, 95% CI: 1.469 to 4.250, $p =$
Patients with a higher pathologic N stage had more postoperative complications. The patients with pathologic N2 stage had 7.758 times (95% CI: 3.379 to 17.808, $p < 0.001$) the risk of postoperative complications as the patients with pathologic N0 stage, and those with pathologic N3 stage had 8.752 times (95% CI: 2.677 to 28.612, $p < 0.001$) the risk of the pathologic N0 stage patients. In complication group, the mean amount of metastatic and retrieved lymph nodes were 4.27 and 19.00 in patients with higher pathologic N1 stage, respectively. The patients with pathologic prognostic stage III had 3.769 times (95% CI: 1.428 to 9.947, $p = 0.007$) the risk of postoperative complications as the patients with pathologic prognostic stage 0 or no residual tumor (NRT) after neoadjuvant chemotherapy. Although the patients with axillary lymph node dissection (ALND), PMRT or adjuvant chemotherapy were associated with a higher risk of complications in univariate analysis, however, ALND, PMRT, or adjuvant chemotherapy were not significantly different between the two groups in multivariate analysis. In multivariate analysis, only the pathologic N stage was associated with postoperative complications ($p < 0.001$) (Table 5). The regimens of adjuvant chemotherapy were independently analyzed, as a result, doxorubicin, cyclophosphamide, and docetaxel regimen (AC-D) had 3.304 times (95% CI: 1.483 to 7.361, $p = 0.003$) the risk of postoperative complications (Tables 6).

Discussion

In our study, only the pathologic N stage was significantly associated with higher risk of postoperative complications in patients who received mastectomy and IR using tissue expander. Chemotherapy and radiotherapy did not significantly affect postoperative complications. Of the 1,081 patients, 483 patients received adjuvant chemotherapy or radiotherapy and only six out of 483 patients delayed their adjuvant treatment because of postoperative complications.

Breast cancer patients have been able to select immediate breast reconstruction more easily without worrying cost because insurance has covered breast reconstruction for breast cancer patients since April 2015 in Korea. Several studies have demonstrated oncologic safety in the patients who underwent IR following mastectomy [15-17]. In addition, the majority of previous studies on the impact of chemotherapy or radiotherapy on postoperative complications after immediate breast reconstruction reported that chemotherapy or radiotherapy did not increase postoperative complications and immediate breast reconstruction did not affect the initiation of adjuvant treatment [5, 9-12, 18-25]. This study also reported that chemotherapy or radiotherapy did not affect postoperative complications in the patients who underwent immediate breast reconstruction with tissue expander.

Several studies reported that age, BMI, smoking, and DM were risk factors of postoperative complications in patients who underwent immediate breast reconstruction with tissue expanders or implants. Old age, increasing BMI, smoking, and DM can affect postoperative complications related to wound healing, leading to the removal of tissue expanders or implants [9, 26-28]. In this study, the mean age and BMI were 43.29 years and 21.98 kg/m², respectively, indicating that this study was performed mostly on young, normal-weight patients. Because our study had small numbers of patients with DM or current
smokers, the analysis of the impact of DM or smoking on postoperative complications was not powerful enough to determine associations.

Our study showed that the postoperative complication rate was only 5.5% and the median time from mastectomy to complication was 620 days (range 27-2,423 days). In addition, it is reported that only higher N stage was associated with postoperative complications. Lymphatic vessels play an important role in wound healing and wound healing is a complex process including inflammation, coagulation, and formation of granulation tissue with angiogenesis and lymphangiogenesis [29]. Metastatic axillary lymph nodes which have architectural distortion, loss of hilum, or cortical thickness can affect scar formation and sensory nerves in surrounding tissues, therefore, the higher the N stage, the more the removal of this axillary lymph nodes affects the lymph drainage of the arm, which can result in postoperative complication such as breast edema and delayed wound healing [30]. In addition, previous studies have demonstrated that sentinel lymph node biopsy and ALND have association with postoperative complication such as lymphedema, wound infection, and seroma formation [31, 32]. In our study, the most common cause of complications was infections, 2.1%. Some studies have reported that the incidence of seroma formation was 3 – 85% after breast or axillary surgery and seroma aspiration was a risk factor for SSI [33-36], and in our study, only one of 1,081 patients after IR had seroma formation in surgical site and underwent surgical removal of tissue expander. To improve the completion of breast reconstruction, surgeons try to prevent seroma formation at the surgical site by minimizing the dead space and educating patients on how to exercise the arm that is ipsilateral to the breast cancer [35, 37]. Other studies have demonstrated that early drain removal is safe to prevent seroma formation, however, there was no investigation of the timing of drain removal in our study [38, 39].

Although the probability of chemotherapy or radiotherapy increases as the pathologic prognostic stage increases, chemotherapy or radiotherapy was not significantly related to postoperative complication in this study. It has been a controversy whether it is appropriate to do an IR or to do a delayed breast reconstruction in patients with advanced breast cancer. Chemotherapy may be associated toxicity, immunosuppression, and fat necrosis, which may lead to wound healing and PMRT may cause local damage such as fat necrosis, wound dehiscence, flap fibrosis [40, 41]. Therefore, clinicians have not actively recommended IR in patients who were expected to have adjuvant chemotherapy or radiotherapy because it is possible to increase the probability of recurrence by missing the appropriate timing of adjuvant chemotherapy or radiotherapy. However, surgical technique about breast reconstruction with tissue expander has improved over the past years, resulting in more natural, reassuring, and better results. Therefore, breast reconstruction surgery has recently been an indispensable part of breast cancer surgery. In addition to the development of surgical technique, chemotherapy or radiotherapy did not significantly increase postoperative complication and delay timing of adjuvant treatment in our study. In this study, 35 out of 59 patients who had postoperative complications underwent adjuvant chemotherapy or radiotherapy, and only six of 35 patients delayed their adjuvant treatment because of postoperative complication. Five patients suffered from infections during adjuvant chemotherapy and one patient with a headache was diagnosed with brain metastasis during adjuvant radiotherapy. Another 29 of 35
patients who underwent adjuvant treatment developed postoperative complications after adjuvant treatment.

In this study, adjuvant AC-D regimens significantly impact postoperative complications. Specific chemotherapeutic agents may adversely impact wound healing on an immediate tissue expander or implant reconstruction. Changing the chemotherapeutic agents according to side effects may improve postoperative complication and outcomes [9, 42].

This study had some limitations. It was a retrospective review and thus, had selection bias. Also, there are other variables in immediate autologous breast reconstructions because this study was limited to IR with tissue expander. Further studies overcoming these limitations can help to determine the effects of IR.

Conclusions

Several previous studies have reported oncologic safety and no difference in complications after IR following mastectomy in patients with breast cancer [15-17]. However, many surgeons still hesitate to perform immediate breast reconstruction for patients with high-stage breast cancer. Our data suggested that chemotherapy or radiotherapy were not risk factors for postoperative complications, and did not cause delay adjuvant treatment. This study will help patients who are concerned about the complications of IR caused by chemotherapy or radiotherapy determine whether or not to have IR.

Abbreviations

IR: Immediate reconstruction; LVI: Lymphovascular invasion; ALND: Axillary lymph node dissection; NCCN: National Comprehensive Cancer Network; BMI: Body mass index; WHO: World Health Organization; DM: Diabetes mellitus; PMRT: Post-mastectomy radiotherapy; NRT: No residual tumor

Declarations

Ethics approval and consent to participate

The data, including demographic factors, pathologic findings, and perioperative treatment were collected from the electronic medical records after Institutional Review Board Approval in Samsung Medical Center (IRB file no. 2019-10-146). Signed informed consent from the patients was not required.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Competing interests

The authors declare that they have no competing interests.

Funding

No funding was obtained for this study.

Authors' contributions

SMJ, BJJ, and JEL contributed to the conception and design of the study. SMJ, JSW, JMR, SKL, BJC, JHY, SWK, SJN, JKP, GHM and SIB collected and analyzed the data. SMJ, BJJ and JEL wrote and reviewed the manuscript. All authors reviewed and approved the final version of the manuscript.

Acknowledgements

The authors are grateful to all participating patients.

References

1. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999-2017): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz, released in June 2020.

2. Coughlin SS: Epidemiology of Breast Cancer in Women. In: Breast Cancer Metastasis and Drug Resistance: Challenges and Progress. edn. Edited by Ahmad A. Cham: Springer International Publishing; 2019: 9-29.

3. Heimes AS, Stewen K, Hasenburg A: Psychosocial Aspects of Immediate versus Delayed Breast Reconstruction. Breast Care (Basel) 2017, 12(6):374-377.

4. Bykowski MR, Emelife PI, Emelife NN, Chen W, Panetta NJ, de la Cruz C: Nipple-areola complex reconstruction improves psychosocial and sexual well-being in women treated for breast cancer. J Plast Reconstr Aesthet Surg 2017, 70(2):209-214.

5. Baek SH, Bae SJ, Yoon CI, Park SE, Cha CH, Ahn SG, Kim YS, Roh TS, Jeong J: Immediate Breast Reconstruction Does Not Have a Clinically Significant Impact on Adjuvant Treatment Delay and Subsequent Survival Outcomes. J Breast Cancer 2019, 22(1):109-119.

6. Cemal Y, Albornoz CR, Disa JJ, McCarthy CM, Mehrara BJ, Pusic AL, Cordeiro PG, Matros E: A paradigm shift in U.S. breast reconstruction: Part 2. The influence of changing mastectomy patterns on reconstructive rate and method. Plast Reconstr Surg 2013, 131(3):320e-326e.

7. Nguyen AT, Chang DW: Discussion: A paradigm shift in U.S. breast reconstruction: increasing implant rates. Plast Reconstr Surg 2013, 131(1):24-25.
8. Heimes A-S, Stewen K, Hasenburg A: Psychosocial Aspects of Immediate versus Delayed Breast Reconstruction. *Breast care (Basel, Switzerland)* 2017, 12(6):374-377.

9. Dolen UC, Schmidt AC, Um GT, Sharma K, Naughton M, Zoberi I, Margenthaler JM, Myckatyn TM: Impact of Neoadjuvant and Adjuvant Chemotherapy on Immediate Tissue Expander Breast Reconstruction. *Ann Surg Oncol* 2016, 23(7):2357-2366.

10. Mitchem J, Herrmann D, Margenthaler JA, Aft RL: Impact of neoadjuvant chemotherapy on rate of tissue expander/implant loss and progression to successful breast reconstruction following mastectomy. *Am J Surg* 2008, 196(4):519-522.

11. Hamahata A, Kubo K, Takei H, Saitou T, Hayashi Y, Matsumoto H, Nagai S, Inoue K, Kurosumi M, Yamaki T *et al.*: Impact of immediate breast reconstruction on postoperative adjuvant chemotherapy: a single center study. *Breast Cancer* 2015, 22(3):287-291.

12. Jethwa KR, Kahila MM, Whitaker TJ, Harmsen WS, Corbin KS, Park SS, Yan ES, Lemaire V, Boughey JC, Mutter RW: Immediate tissue expander or implant-based breast reconstruction does not compromise the oncologic delivery of post-mastectomy radiotherapy (PMRT). *Breast cancer research and treatment* 2017, 164(1):237-244.

13. National Comprehensive Cancer Network. Breast Cancer Version5.2020. [http://www.nccn.org/professionals/physician_gls/PDF](http://www.nccn.org/professionals/physician_gls/PDF) Accessed July 15th, 2020.

14. Dindo D, Demartines N, Clavien P-A: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004, 240(2):205-213.

15. Ryu JM, Paik HJ, Park S, Yi HW, Nam SJ, Kim SW, Lee SK, Yu J, Bae SY, Lee JE: Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study. *J Breast Cancer* 2017, 20(1):74-81.

16. Ryu JM, Park S, Paik HJ, Nam SJ, Kim SW, Lee SK, Yu J, Bae SY, Kim I, Bang SI *et al.*: Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case-Control Study. *Clin Breast Cancer* 2017, 17(3):204-210.

17. Lee SB, Lee JW, Son BH, Eom JS, Kim EK, Lee TJ, Ahn S-H: Oncologic safety of skin-sparing mastectomy followed by immediate reconstruction in young patients with breast cancer. *Asian J Surg* 2019, 42(1):274-282.

18. Furey PC, Macgillivray DC, Castiglione CL, Allen L: Wound complications in patients receiving adjuvant chemotherapy after mastectomy and immediate breast reconstruction for breast cancer. *Journal of surgical oncology* 1994, 55(3):194-197.

19. Decker MR, Greenblatt DY, Havlena J, Wilke LG, Greenberg CC, Neuman HB: Impact of neoadjuvant chemotherapy on wound complications after breast surgery. *Surgery* 2012, 152(3):382-388.

20. Song J, Zhang X, Liu Q, Peng J, Liang X, Shen Y, Liu H, Li H: Impact of neoadjuvant chemotherapy on immediate breast reconstruction: a meta-analysis. *PloS one* 2014, 9(5):e98225-e98225.

21. Warren Peled A, Itakura K, Foster RD, Hamolsky D, Tanaka J, Ewing C, Alvarado M, Esserman LJ, Hwang ES: Impact of chemotherapy on postoperative complications after mastectomy and
immediate breast reconstruction. Arch Surg 2010, 145(9):880-885.

22. Yoon AP, Qi J, Brown DL, Kim HM, Hamill JB, Erdmann-Sager J, Pusic AL, Wilkins EG: Outcomes of immediate versus delayed breast reconstruction: Results of a multicenter prospective study. Breast (Edinburgh, Scotland) 2018, 37:72-79.

23. Anker CJ, Hymas RV, Ahluwalia R, Kokeny KE, Avizonis V, Boucher KM, Neumayer LA, Agarwal JP: The Effect of Radiation on Complication Rates and Patient Satisfaction in Breast Reconstruction using Temporary Tissue Expanders and Permanent Implants. The breast journal 2015, 21(3):233-240.

24. Lam TC, Borotkanics R, Hsieh F, Salinas J, Boyages J: Immediate Two-Stage Prosthetic Breast Reconstruction Failure: Radiation Is Not the Only Culprit. Plastic and reconstructive surgery 2018, 141(6):1315-1324.

25. Allué Cabañuz M, Arribas Del Amo MD, Gil Romea I, Val-Carreres Rivera MP, Sousa Domínguez R, Güemes Sánchez AT: Direct-to-implant breast reconstruction after neoadjuvant chemotherapy: A safe option? Cir Esp 2019, 97(10):575-581.

26. Garvey PB, Villa MT, Rozanski AT, Liu J, Robb GL, Beahm EK: The advantages of free abdominal-based flaps over implants for breast reconstruction in obese patients. Plastic and reconstructive surgery 2012, 130(5):991-1000.

27. Ilonzo N, Tsang A, Tsantes S, Estabrook A, Thu Ma AM: Breast reconstruction after mastectomy: A ten-year analysis of trends and immediate postoperative outcomes. Breast (Edinburgh, Scotland) 2017, 32:7-12.

28. Sada A, Day CN, Hoskin TL, Degnim AC, Habermann EB, Hieken TJ: Mastectomy and immediate breast reconstruction in the elderly: Trends and outcomes. Surgery 2019, 166(4):709-714.

29. Lee S-J, Park C, Lee JY, Kim S, Kwon PJ, Kim W, Jeon YH, Lee E, Yoon Y-s: Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair. Sci Rep 2015, 5:11019-11019.

30. Young-Afat DA, Gregorowitsch ML, van den Bongard DH, Burgmans I, van der Pol CC, Witkamp AJ, Bijlsma RM, Koelemij R, Schoenmaeckers EJ, Jonasse Y et al: Breast Edema Following Breast-Conserving Surgery and Radiotherapy: Patient-Reported Prevalence, Determinants, and Effect on Health-Related Quality of Life. JNCI Cancer Spectr 2019, 3(2):pkz011.

31. Killelea BK, Long JB, Dang W, Mougalian SS, Evans SB, Gross CP, Wang S-Y: Associations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ. Annals of surgical oncology 2018, 25(6):1521-1529.

32. Cuadrado GdA, de Andrade MFC, Akamatsu FE, Jacomo AL: Lymph drainage of the upper limb and mammary region to the axilla: anatomical study in stillborns. Breast Cancer Research and Treatment 2018, 169(2):251-256.

33. Ota D, Fukuuchi A, Iwahira Y, Kato T, Takeuchi M, Okamoto J, Nishi T: Identification of complications in mastectomy with immediate reconstruction using tissue expanders and permanent implants for breast cancer patients. Breast Cancer 2016, 23(3):400-406.
34. Moyer KE, Potochny JD: Technique for seroma drainage in implant-based breast reconstruction. *J Plast Reconstr Aesthet Surg* 2012, 65(12):1614-1617.

35. ten Wolde B, van den Wildenberg FJ, Keemers-Gels ME, Polat F, Strobbe LJ: Quilting prevents seroma formation following breast cancer surgery: closing the dead space by quilting prevents seroma following axillary lymph node dissection and mastectomy. *Ann Surg Oncol* 2014, 21(3):802-807.

36. Boostrom SY, Throckmorton AD, Boughey JC, Holifield AC, Zakaria S, Hoskin TL, Degnim AC: Incidence of clinically significant seroma after breast and axillary surgery. *J Am Coll Surg* 2009, 208(1):148-150.

37. Coveney EC, O'Dwyer PJ, Geraghty JG, O'Higgins NJ: Effect of closing dead space on seroma formation after mastectomy—a prospective randomized clinical trial. *Eur J Surg Oncol* 1993, 19(2):143-146.

38. Thomson DR, Trevatt AE, Furniss D: When should axillary drains be removed? A meta-analysis of time-limited versus volume controlled strategies for timing of drain removal following axillary lymphadenectomy. *J Plast Reconstr Aesthet Surg* 2016, 69(12):1614-1620.

39. Unalp HR, Onal MA: Analysis of risk factors affecting the development of seromas following breast cancer surgeries: seromas following breast cancer surgeries. *Breast J* 2007, 13(6):588-592.

40. El-Sabawi B, Sosin M, Carey JN, Nahabedian MY, Patel KM: Breast reconstruction and adjuvant therapy: A systematic review of surgical outcomes. *J Surg Oncol* 2015, 112(5):458-464.

41. Sekiguchi K, Kawamori J, Yamauchi H: Breast reconstruction and postmastectomy radiotherapy: complications by type and timing and other problems in radiation oncology. *Breast Cancer* 2017, 24(4):511-520.

42. Oh E, Chim H, Soltanian HT: The effects of neoadjuvant and adjuvant chemotherapy on the surgical outcomes of breast reconstruction. *J Plast Reconstr Aesthet Surg* 2012, 65(10):e267-280.

**Tables**

Table 1 Baseline characteristics of patients
| Variable          | Total, N Mean±SD | No complication group, N (%) Mean±SD | Complication group, N (%) Mean±SD | p     |
|-------------------|------------------|-------------------------------------|-----------------------------------|-------|
| Number of Patients| 1081             | 1022 (94.5)                        | 59 (5.5)                          | 0.998 |
| Age (years)       | 43.29±7.40       | 43.29±7.35                         | 42.29±8.30                        | 0.985 |
| Age group         |                  |                                     |                                   |       |
| <40 years         | 331              | 313 (94.6)                         | 18 (5.4)                          |       |
| ≥40 years         | 750              | 709 (94.5)                         | 41 (5.5)                          |       |
| BMI (kg/)         | 21.98±2.93       | 21.96±2.91                         | 22.40±3.19                        | 0.266 |
| BMI group         |                  |                                     |                                   | 0.383 |
| <18.5             | 75               | 73 (97.3)                          | 2 (2.7)                           |       |
| 18.5-22.9         | 668              | 633 (94.8)                         | 35 (5.2)                          |       |
| ≥23               | 338              | 316 (93.5)                         | 22 (6.5)                          |       |
| DM                |                  |                                     |                                   | 0.595 |
| Yes               | 16               | 15 (93.8)                          | 1 (6.3)                           |       |
| No                | 1065             | 1007 (94.6)                        | 58 (5.4)                          |       |
| Smoking           |                  |                                     |                                   | 0.439 |
| Never             | 1048             | 991 (94.6)                         | 57 (5.4)                          |       |
| Prior             | 7                | 6 (85.7)                           | 1 (14.3)                          |       |
| Current           | 26               | 25 (96.2)                          | 1 (3.8)                           |       |

*BMI* body mass index  
*DM* diabetes mellitus  

**Table 2** Clinicopathologic characteristics of patients
| Variable                        | Total, N | No complication group, N (%) | Complication group, N (%) | p     |
|--------------------------------|----------|------------------------------|---------------------------|-------|
| Number of Patients             | 1081     | 1022 (94.5)                  | 59 (5.5)                  |       |
| **Location**                   |          |                              |                           | 0.032 |
| Right                          | 514      | 484 (94.2)                   | 30 (5.8)                  |       |
| Left                           | 499      | 478 (95.8)                   | 21 (4.2)                  |       |
| Bilateral                      | 68       | 60 (88.2)                    | 8 (11.8)                  |       |
| **Histopathology**             |          |                              |                           | 0.939 |
| Invasive cancer                | 841      | 794 (94.4)                   | 47 (5.6)                  |       |
| DCIS                           | 199      | 189 (95.0)                   | 10 (5.0)                  |       |
| Other                          | 41       | 39 (95.1)                    | 2 (4.9)                   |       |
| **Nuclear grade**              |          |                              |                           | 0.966 |
| Low                            | 153      | 144 (94.1)                   | 9 (5.9)                   |       |
| Intermediate                   | 663      | 627 (94.6)                   | 36 (5.4)                  |       |
| High                           | 265      | 251 (94.7)                   | 14 (5.3)                  |       |
| **LVI**                        |          |                              |                           | 0.001 |
| Yes                            | 285      | 258 (90.5)                   | 27 (9.5)                  |       |
| No                             | 796      | 764 (96.0)                   | 32 (4.0)                  |       |
| **Pathologic T**               |          |                              |                           | 0.118 |
| Tis & pCR                      | 212      | 207 (97.6)                   | 5 (2.4)                   |       |
| T1                             | 514      | 484 (94.2)                   | 30 (5.8)                  |       |
| T2                             | 299      | 280 (93.6)                   | 19 (6.4)                  |       |
| ≥T3                            | 56       | 51 (91.1)                    | 5 (8.9)                   |       |
| **Pathologic N**               |          |                              |                           | <0.001|
| N0                             | 795      | 768 (96.6)                   | 27 (3.4)                  |       |
| N1                             | 227      | 208 (91.6)                   | 19 (8.4)                  |       |
| N2                             | 42       | 33 (78.6)                    | 9 (21.4)                  |       |
| N3                             | 17       | 13 (76.5)                    | 4 (23.5)                  |       |
| **Pathologic prognostic stage**|          |                              |                           | 0.017 |
| 0 & NRT                        | 207      | 199 (96.1)                   | 8 (3.9)                   |       |
| I                              | 456      | 431 (94.5)                   | 25 (5.5)                  |       |
| II                             | 342      | 326 (95.3)                   | 16 (4.7)                  |       |
| III                            | 76       | 66 (86.8)                    | 10 (13.2)                 |       |
| **ER**                         |          |                              |                           | 0.445 |
| Positive                       | 895      | 844 (94.3)                   | 51 (5.7)                  |       |
| Negative                       | 186      | 178 (95.7)                   | 8 (4.3)                   |       |
| **PR**                         |          |                              |                           | 0.192 |
| Positive                       | 842      | 792 (94.1)                   | 50 (5.9)                  |       |
| Negative                       | 239      | 230 (96.2)                   | 9 (3.8)                   |       |
| **C-erbB-2**                   |          |                              |                           | 0.586 |
| Positive                       | 296      | 280 (94.6)                   | 16 (5.4)                  |       |
| Negative                       | 664      | 630 (94.9)                   | 34 (5.1)                  |       |
| Unknown                        | 121      | 112 (92.6)                   | 9 (7.4)                   |       |
| **Subtype**                    |          |                              |                           | 0.880 |
| HR (+)                         | 900      | 849 (94.3)                   | 51 (5.7)                  |       |
| HR(-) C-erbB-2(+)              | 121      | 116 (95.9)                   | 5 (4.1)                   |       |
| HR(-) C-erbB-2(-)              | 56       | 53 (94.6)                    | 3 (5.4)                   |       |
| Unknown                        | 4        | 4 (100.0)                    | 0 (0.0)                   |       |

*DCIS* ductal carcinoma in situ  
*LVI* lymphovascular invasion
$pCR$ pathologic complete response

$NRT$ no residual tumor

$HR$ Hormonal receptor

**Table 3** Characteristics of surgical and medical treatment

| Variable                        | Total, N | No complication group, N (%) | Complication group, N (%) | $p$  |
|---------------------------------|----------|------------------------------|---------------------------|------|
| Number of Patients              | 1081     | 1022 (94.5)                  | 59 (5.5)                  |      |
| **Axillary operation**          |          |                              |                           |      |
| SLNB                            | 876      | 839 (95.8)                   | 37 (4.2)                  |      |
| ALND                            | 205      | 183 (89.3)                   | 22 (10.7)                 |      |
| **PMRT**                        |          |                              |                           | <0.001|
| Yes                             | 193      | 172 (89.1)                   | 21 (10.9)                 |      |
| No                              | 888      | 850 (95.7)                   | 38 (4.3)                  |      |
| **Chemotherapy**                |          |                              |                           |      |
| No                              | 599      | 575 (96.0)                   | 24 (4.0)                  |      |
| NAC                             | 61       | 57 (93.4)                    | 4 (6.6)                   |      |
| Adjuvant chemotherapy           | 421      | 390 (92.6)                   | 31 (7.4)                  |      |

*SLNB* sentinel lymph node biopsy

*ALND* axillary lymph node dissection

*PMRT* post-mastectomy radiotherapy

*NAC* neoadjuvant chemotherapy

**Table 4** Type of postoperative complication
| Complication type          | Total, N | Surgical removal, N | No removal, N |
|---------------------------|----------|---------------------|--------------|
|                           | 59       | 48                  | 11           |
| Recurrence or Metastasis  | 4        | 4                   | 0            |
| Infection                 | 23       | 17                  | 6            |
| Capsular contracture      | 10       | 10                  | 0            |
| Rupture                   | 3        | 3                   | 0            |
| Malposition               | 6        | 5                   | 1            |
| Arm motion limitation     | 1        | 1                   | 0            |
| Hematoma                  | 1        | 0                   | 1            |
| Wound dehiscence          | 3        | 2                   | 1            |
| Wound necrosis            | 4        | 3                   | 1            |
| Skin erythema & Seroma    | 1        | 1                   | 0            |
| Cosmetic surgery*         | 2        | 1                   | 1            |
| Desmoid tumor             | 1        | 1                   | 0            |

* Cosmetic surgery: rippling, scar revision

**Table 5** Univariate and multivariate analysis of risk factors for postoperative complication
| Location         | Univariate HR (95% CI) | Univariate p  | Multivariate HR (95% CI) | Multivariate p |
|------------------|------------------------|---------------|--------------------------|----------------|
| Right (Ref.)     |                        | 0.039         |                          | 0.020          |
| Left             | 0.709 (0.400-1.256)    | 0.238         | 0.659 (0.366-1.185)      | 0.163          |
| Bilateral        | 2.151 (0.943-4.907)    | 0.069         | 2.331 (0.989-5.490)      | 0.053          |
| **Histopathology** |                        |               |                          |               |
| Invasive cancer (Ref.) | 0.939                |               |                          | 0.921          |
| DCIS             | 0.894 (0.444-1.801)    | 0.754         | 1.188 (0.508-2.780)      | 0.691          |
| Other            | 0.866 (0.203-3.698)    | 0.846         | 1.079 (0.241-4.842)      | 0.921          |
| **LVI**          |                        |               |                          |               |
| Yes              | 2.499 (1.469-4.250)    | 0.001         | 1.709 (0.946-3.085)      | 0.076          |
| No (Ref.)        |                        |               |                          |               |
| **Pathologic N** |                        |               |                          |               |
| N0 (Ref.)        |                        | <0.001        |                          | <0.001         |
| N1               | 2.598 (1.417-4.766)    | 0.002         | 2.203 (1.163-4.172)      | 0.015          |
| N2               | 7.758 (3.379-17.808)   | <0.001        | 6.823 (2.845-16.361)     | <0.001         |
| N3               | 8.752 (2.677-28.612)   | <0.001        | 6.331 (1.831-21.886)     | 0.004          |
| **Pathologic prognostic stage** |                  |               |                          |               |
| 0 & NRT (Ref.)   |                        | 0.025         |                          | 0.179          |
| I                | 1.443 (0.640-3.255)    | 0.377         | 1.232 (0.461-3.288)      | 0.677          |
| II               | 1.221 (0.513-2.905)    | 0.652         | 0.054 (0.170-1.713)      | 0.295          |
| III              | 3.769 (1.428-9.947)    | 0.007         | 0.564 (0.145-2.200)      | 0.410          |
| **Axillary op**  |                        |               |                          |               |
| SLNB (Ref.)      |                        |               |                          |               |
| ALND             | 3.144 (1.826-5.414)    | <0.001        | 1.450 (0.674-3.123)      | 0.342          |
| **PMRT +**       |                        |               |                          |               |
| Yes              | 2.731 (1.564-4.769)    | <0.001        | 1.101 (0.468-2.589)      | 0.825          |
| No (Ref.)        |                        |               |                          |               |
| **CTx.**         |                        |               |                          |               |
| No (Ref.)        |                        | 0.067         |                          | 0.775          |
| NAC              | 1.681 (0.564-5.015)    | 0.351         | 0.625 (0.168-2.328)      | 0.483          |
| Adjuvant CTx.    | 1.904 (1.101-3.295)    | 0.021         | 0.839 (0.384-1.833)      | 0.660          |

*DCIS* ductal carcinoma in situ  
*LVI* lymphovascular invasion  
*NRT* no residual tumor  
*SLNB* sentinel lymph node biopsy  
*ALND* axillary lymph node dissection  
*PMRT* post-mastectomy radiotherapy  
*NAC* neoadjuvant chemotherapy
Table 6 Risk factors for postoperative complication by regimens of adjuvant chemotherapy

| Regimen | N   | Odds ratios (95% CI)       | p    |
|---------|-----|---------------------------|------|
| Patients| 421 |                           |      |
| AC      | 126 | 0.323 (0.111-0.943)       | 0.039|
| AC-D    | 187 | 3.304 (1.483-7.361)       | 0.003|
| AC-P    | 24  | 1.147 (0.257-5.122)       | 0.857|
| FAC     | 47  | 0.526 (0.121-2.278)       | 0.390|
| TC      | 22  | 0.583 (0.076-4.482)       | 0.604|
| TCH     | 13  | 0.000 (0.000-0.000)       | 0.999|
| f/u loss| 2   |                           |      |

Figures

Figure 1

Breast cancer surgery (N=11,360) (Jan. 2012 - Dec. 2017)

No mastectomy (N=10,171)

Mastectomy with IR (N=1,185)

Exclusion (N=104)
  : Autologous reconstruction, Incomplete record

Mastectomy with IR using tissue expander (N=1,081)

No complication group (N=1,022)

Complication group (N=59)
Schematic flow of patients